{"DataElement":{"publicId":"7297254","version":"1","preferredName":"Eligibility Criteria Protocol Approval Malignant Neoplasm CPTAC Indicator","preferredDefinition":"A response to indicate whether the candidate has been or likely to be diagnosed with a protocol approved malignancy.","longName":"7297250v1.0:6841630v1.0","context":"OCCPR","contextVersion":"1","DataElementConcept":{"publicId":"7297250","version":"1","preferredName":"Eligibility Criteria Protocol Approval Malignant Neoplasm","preferredDefinition":"Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria._A rule which guides how an activity should be performed._Acceptance as satisfactory by an authoritative body; established by authority; given authoritative approval._A tumor composed of atypical neoplastic, often pleomorphic cells that invade other tissues. Malignant neoplasms often metastasize to distant anatomic sites and may recur after excision. The most common malignant neoplasms are carcinomas (adenocarcinomas or squamous cell carcinomas), Hodgkin and non-Hodgkin lymphomas, leukemias, melanomas, and sarcomas.","longName":"2767728v1.0:7297248v1.0","context":"OCCPR","contextVersion":"1","ObjectClass":{"publicId":"2767728","version":"1","preferredName":"Clinical Trial Eligibility Criteria","preferredDefinition":"Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","longName":"C16112","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Clinical Trial Eligibility Criteria","conceptCode":"C16112","definition":"Characteristics which are necessary to allow a subject to participate in a clinical study, as outlined in the study protocol. The concept covers inclusion and exclusion criteria.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"529EA070-682D-67A0-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2008-07-22","endDate":null,"createdBy":"UMLLOADER_WCI","dateCreated":"2008-07-22","modifiedBy":"ONEDATA","dateModified":"2008-07-22","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"7297248","version":"1","preferredName":"Protocol Approval Malignant Neoplasm","preferredDefinition":"A rule which guides how an activity should be performed.:Acceptance as satisfactory by an authoritative body; established by authority; given authoritative approval.:A tumor composed of atypical neoplastic, often pleomorphic cells that invade other tissues. Malignant neoplasms often metastasize to distant anatomic sites and may recur after excision. The most common malignant neoplasms are carcinomas (adenocarcinomas or squamous cell carcinomas), Hodgkin and non-Hodgkin lymphomas, leukemias, melanomas, and sarcomas.","longName":"C42651:C25425:C9305","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Protocol","conceptCode":"C42651","definition":"A rule which guides how an activity should be performed.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Approval","conceptCode":"C25425","definition":"Acceptance as satisfactory by an authoritative body; established by authority; given authoritative approval.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Malignant Neoplasm","conceptCode":"C9305","definition":"A neoplasm composed of atypical neoplastic, often pleomorphic cells that invade other tissues. Malignant neoplasms often metastasize to distant anatomic sites and may recur after excision. The most common malignant neoplasms are carcinomas, Hodgkin and non-Hodgkin lymphomas, leukemias, melanomas, and sarcomas.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"A69160EE-9699-3EBE-E053-4EBD850A42B7","latestVersionIndicator":"Yes","beginDate":"2020-05-26","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-05-26","modifiedBy":"ONEDATA","dateModified":"2020-05-26","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008525","version":"1","preferredName":"Eligibility","preferredDefinition":"trial-specific criteria that a patient must meet to be enrolled.","longName":"ELIG","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B1EC3968-9F25-305A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-16","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-16","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"A69160EE-96AA-3EBE-E053-4EBD850A42B7","latestVersionIndicator":"Yes","beginDate":"2020-05-26","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-05-26","modifiedBy":"KNABLEJ","dateModified":"2020-06-12","changeDescription":"6/11/20 jk Released per SME (NGM) review and approval email.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"6841630","version":"1","preferredName":"CPTAC Yes No Unk Indicator","preferredDefinition":"A national effort to accelerate the understanding of the molecular basis of cancer through the application of large-scale proteome and genome analysis, or proteogenomics._An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","longName":"6841630v1.0","context":"OCCPR","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"50","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Unknown","valueDescription":"Unknown","ValueMeaning":{"publicId":"3104212","version":"1","preferredName":"Unknown","longName":"3104212v1.00","preferredDefinition":"Not known, observed, recorded; or reported as unknown by the data contributor.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Unknown","conceptCode":"C17998","definition":"Not known, observed, recorded; or reported as unknown by the data contributor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"87F3C580-06F4-1DC3-E040-BB89AD434E7E","latestVersionIndicator":"Yes","beginDate":"2010-06-01","endDate":null,"createdBy":"REEVESD","dateCreated":"2010-06-01","modifiedBy":"FINCHAMB","dateModified":"2024-01-19","changeDescription":"Concept annotated for UPitt/TCGA.  Ylu, 01/30/2015.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8F0FF8F1-5A82-3678-E053-F662850A4C36","beginDate":"2019-08-01","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-08-01","modifiedBy":"ONEDATA","dateModified":"2019-08-01","deletedIndicator":"No"},{"value":"Yes","valueDescription":"Yes","ValueMeaning":{"publicId":"5682957","version":"1","preferredName":"Yes","longName":"5682957","preferredDefinition":"The affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Yes","conceptCode":"C49488","definition":"The affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"498B4DAE-2A6B-7561-E053-F662850A0EBD","latestVersionIndicator":"Yes","beginDate":"2017-02-27","endDate":null,"createdBy":"ALEYR","dateCreated":"2017-02-27","modifiedBy":"DWARZEL","dateModified":"2018-10-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8EFB6B26-0CA9-5A31-E053-F662850A5C7D","beginDate":"2019-07-31","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-07-31","modifiedBy":"ONEDATA","dateModified":"2019-07-31","deletedIndicator":"No"},{"value":"No","valueDescription":"No","ValueMeaning":{"publicId":"5682943","version":"1","preferredName":"No","longName":"5682943","preferredDefinition":"The non-affirmative response to a question.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"No","conceptCode":"C49487","definition":"The non-affirmative response to a question.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"498B0E12-9AC2-79DC-E053-F662850A0B75","latestVersionIndicator":"Yes","beginDate":"2017-02-27","endDate":null,"createdBy":"ALEYR","dateCreated":"2017-02-27","modifiedBy":"DWARZEL","dateModified":"2018-10-01","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"8EFB6B26-0CB3-5A31-E053-F662850A5C7D","beginDate":"2019-07-31","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-07-31","modifiedBy":"ONEDATA","dateModified":"2019-07-31","deletedIndicator":"No"},{"value":"Unknown: Could not be determined or unsure","valueDescription":"Indeterminate or Unknown","ValueMeaning":{"publicId":"6841632","version":"1","preferredName":"Indeterminate or Unknown","longName":"6841632","preferredDefinition":"An indication that something is indeterminate or unknown.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Indeterminate or Unknown","conceptCode":"C157157","definition":"An indication that something is indeterminate or unknown.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8EFB6B26-0C86-5A31-E053-F662850A5C7D","latestVersionIndicator":"Yes","beginDate":"2019-07-31","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-07-31","modifiedBy":"ONEDATA","dateModified":"2019-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"9A782DA4-CE67-084E-E053-F662850AB283","beginDate":"2019-07-31","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2019-12-24","modifiedBy":"ONEDATA","dateModified":"2019-12-24","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008551","version":"1","preferredName":"Assessments","preferredDefinition":"evaluations of the patient and the patient's disease.","longName":"ASSESS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22DA727-6718-5A2D-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"6841629","version":"1","preferredName":"Clinical Proteomic Tumor Analysis Consortium Indicator","preferredDefinition":"A national effort to accelerate the understanding of the molecular basis of cancer through the application of large-scale proteome and genome analysis, or proteogenomics.:An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","longName":"C157175:C25180","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Clinical Proteomic Tumor Analysis Consortium","conceptCode":"C157175","definition":"A national effort to accelerate the understanding of the molecular basis of cancer through the application of large-scale proteome and genome analysis, or proteogenomics.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Indicator","conceptCode":"C25180","definition":"An event, entity or condition that typically characterizes a prescribed environment or situation and determines or aids in determining whether certain stated circumstances exist or criteria are satisfied.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"8EFB6B26-0C5B-5A31-E053-F662850A5C7D","latestVersionIndicator":"Yes","beginDate":"2019-07-31","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-07-31","modifiedBy":"ONEDATA","dateModified":"2019-07-31","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Application","id":"8EFB6B26-0C6C-5A31-E053-F662850A5C7D","latestVersionIndicator":"Yes","beginDate":"2019-07-31","endDate":null,"createdBy":"TAYLORT","dateCreated":"2019-07-31","modifiedBy":"GDEEN","dateModified":"2023-11-14","changeDescription":"11/10/19 jk Released per CPTAC SME (Linda) for Medical History CRF.  7-31-19 tt created for CPTAC Medical History CRF.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"6601273","version":"1","longName":"CPTAC (Clinical Proteomic Tumor Analysis Consortium)","context":"OCCPR","ClassificationSchemeItems":[{"publicId":"6776734","version":"1","longName":"All Generic CRFs","context":"OCCPR"},{"publicId":"7203746","version":"1","longName":"Screening and Eligibility","context":"OCCPR"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Has candidate recently been o","type":"Preferred Question Text","description":"Has candidate recently been or is the candidate likely to be diagnosed with a protocol approved malignancy?","url":null,"context":"OCCPR"}],"origin":"CPTAC: Clinical Proteomic Tumor Analysis Consortium","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"A691AEED-94E4-659E-E053-4EBD850A9ECD","latestVersionIndicator":"Yes","beginDate":"2020-05-26","endDate":null,"createdBy":"KUMMEROA","dateCreated":"2020-05-26","modifiedBy":"JKNABLE","dateModified":"2022-07-08","changeDescription":"6/11/20 jk Released per SME (NGM) review and approval email.","administrativeNotes":"7/8/22 Edits made to definition for format consistency per CPTAC SME. jk","unresolvedIssues":null,"deletedIndicator":"No"}}